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Available online 8 September 2016Background:We report diagnosis andmanagement of stage IV papillary serous uterine cancer with initial clinical
presentation as a skin rash.
Case:A 62-year-old postmenopausal female developed an erythematous rash beginning on her right lower abdo-
men and progressively spreading to her left abdomen, vulva, and neck. After a trial of antibiotic treatment, biopsy
of left neck and right thigh skin nodules revealed papillary serous carcinoma. Abdominopelvic tomography re-
vealed endometrial thickening and a 5 cm left adnexal mass. Subsequent endometrial biopsy also revealed pap-
illary serous carcinoma,with pathology similar to that of the skin lesions. She received 6 cycles of carboplatin and
paclitaxel chemotherapywith improvement of her skin lesions and overall performance status. However, her CA-
125 level continued to rise and shewas treatedwith single-agent carboplatin with progression of both her inter-
nal and cutaneous disease. She was transitioned to hospice with palliative radiation and died 2 months after
discontinuing chemotherapy, 10 months after presentation.
Conclusion: Cutaneousmetastasis is a rare presentation of metastatic uterine cancer. Treatment with chemother-
apy may result in a positive response and should be considered.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Uterine papillary serous cancer (UPSC) is a type II uterine cancer
generally associated with more aggressive clinical behavior than type I
or endometrioid cancer. Although type II cancers comprise 10–20% of
endometrial cancer cases, they account for 40% of uterine cancer deaths
(Moore and Fader, 2011). Abnormal uterine or postmenopausal bleed-
ing are the most common presentation of both papillary serous and
endometrioid uterine cancer (Keeble et al., 2014). Cutaneousmetastasis
of uterine cancer has been documented in the literature and is a rare oc-
currence. Our literature review revealed 10 reported cases of uterine
cancer with metastasis to the skin over a 36-year period (Rasbach et
al., 1978; Damewood et al., 1980; Debois, 1982; Espinos et al., 1992;
Spencer et al., 1994; Kushner et al., 1997; La Fianza et al., 1998;
Atallah et al., 2014; Elit et al., 2001; Kim et al., 2005). In all of these pre-
vious reports, the diagnosis of uterine cancer preceded thedevelopment
of cutaneous metastases, which were late events. We report the case of
a woman who presented with an abdominal rash found to represent
stage IV UPSC, whose clinical course can provide a basis for discussing
treatment options in this rare presentation.t of Obstetrics and Gynecology,
sville, VA 22908-0712, United
. This is an open access article under2. Case
A 62-year-old gravida 2 para 2 postmenopausal female with a histo-
ry of endometriosis and earlymenopause at 33 years of age presented to
the emergency department with a new-onset groin rash, genital pain,
and dysuria. She denied any other gynecologic symptoms including ab-
normal vaginal discharge and postmenopausal bleeding. At that time,
she reported recently moving into a new home with contaminated
water which stained her clothes. Approximately 3 weeks after moving
she developed an erythematous rash on her right lower abdomen
which progressively spread to her groin and vulva. She noted the devel-
opment of papules and bullous lesions as the rash progressed and noted
the development of a single papule on her left neck. Her primary care
provider prescribed oral clindamycin for the rash but noted worsening
of the rash despite antibiotic treatment. Of note, she experienced an un-
intentional weight loss of 40 lb in the last 6 months. At initial presenta-
tion to our emergency department, physical exam was signiﬁcant for
labial induration with a tender 2 cm vesicular lesion with ﬁbrinous ex-
udates (Fig. 1a), an erythematous maculopapular rash extending from
the inferior abdomen to the groin (Fig. 1b), and several nodular lesions
scattered throughout the perineum. Internal gynecologic examination
revealed a cervix that was bulky at 3–4 cm but without a visible lesion,
and the uterus was enlarged to 12–14 weeks size, with no evidence of
parametrial thickening. A computerized tomography (CT) scanwas per-
formedwhich revealed abnormally enhancing and thickened right labi-
al fold, and morphologically abnormal and enlarged inguinal lymphthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. a: Papular neck left lesion. b: Labial induration with a tender 2 cm vesicular lesion with ﬁbrinous exudates. c: Erythematous maculopapular rash extending from the inferior
abdomen to the groin.
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refused further evaluation at the time. As such, a complete evaluation
was unable to be performed. Given concern for superimposed infection,
a herpes simplex virus culture was obtained from one of the labial le-
sions and she was started on empiric antibiotics for a 10 day course
and scheduled to return for a follow up in our outpatient gynecology
and dermatology clinics.
At the patient's outpatient follow up, she reported no improvement
of her rash or labial pain despite the antibiotics. Herpes simplex virus
culture obtained from her prior emergency department visit returned
positive and patient was prescribed valcyclovir for treatment of pre-
sumed outbreak but this diagnosis did not provide an explanation for
her systemic ﬁndings. A pelvic ultrasound was performed and revealed
a uterine body measuring 7.0 cm by 4.6 cm × 5.4 cm with a thickened
endometrial stripe heterogeneous anddifﬁcult to differentiate from sur-
rounding myometrium. An endometrial biopsy was performed and re-
vealed fragments of markedly atypical epithelium favoring papillary
serous carcinoma (Fig. 2a). A shave biopsy of a left neck lesion and
punch biopsy of the right thigh lesion revealed metastatic papillary se-
rous carcinoma consistent with mullerian primary origin (Fig. 2b). The
patient was subsequently referred to our gynecologic oncology service
for further management.
Given thewidelymetastatic nature of her disease, shewas started on
carboplatin/paclitaxel and completed 6 cycles of chemotherapy. Serial
physical exams showed resolution of rash consistentwith treatment re-
sponse (Fig. 3). CA-125 levels were trended throughout her treatment
course andwas 174U/mL at the conclusion of 6 cycles of chemotherapy.
After 6 cycles, CT imaging of her chest, abdomen, and pelvis was per-
formed and revealed suspicious nodules in her right lung and axilla in
addition to interval resolution of inguinal adenopathy, signiﬁcant reduc-
tion in size of a left adnexal mass, and decreased volume of the uterus. It
is unclear if the right pulmonary and axillary nodules representFig. 2. a: Hematoxylin and eosin stain of endometrial biopsy revealing fragments of markedly a
right thigh skin lesion revealing similar pathologic ﬁndings from endometrial biopsy suggestivprogressive disease or were present initially given a chest CT was not
performedwhen she initially presented. Given the appearance of a pos-
itive response, consideration was given to surgery with hysterectomy
and debulking, but the extent of initial disease raised concern that the
procedure would not remove all residual disease and not be curative.
Additionally the patient did not feel her performance status to be ade-
quate to undergo surgery. A chemotherapy holiday was initiated with
a plan to reevaluate in 2months. However, the patient returned approx-
imately 1month after completion of her chemotherapy reporting recur-
rence of skin lesions. Additionally her CA-125 increased to 624 U/mL.
She was started on single-agent carboplatin given her prior response
to treatment and received 1 cycle prior to rapid progression of disease.
She began to have vaginal bleeding andwas referred to radiation oncol-
ogy for consideration of palliative radiation treatment where she re-
ceived external beam radiation therapy to a dose of 16 Gy in 2
fractions. The patient was offered additional chemotherapy, but with
the low likelihood of a response given rapid regrowth, she requested
transition to hospice care. She had continued deterioration of functional
status and died 2 months after discontinuing chemotherapy treatment.
3. Discussion
In this case, we described the diagnosis and management of a
woman with stage IV UPSC and cutaneous metastasis. This case is
unique in that the initial presentation of the disease was her skin le-
sions. It may be helpful to the community to know that although she
had disseminated disease, she had a positive initial response to chemo-
therapy, and therefore treatment is a reasonable option. However, con-
sistent with her poor prognosis, the patient experienced a rapid
recurrence, decline, and death.
Althoughmost early uterine cancer patients will have vaginal bleed-
ing, some may have none. On initial presentation, this patient made ittypical epithelium favoring serous carcinoma. b: Hematoxylin and eosin stain of biopsied
e of metastatic serous carcinoma.
Fig. 3. Nearly complete resolution of skin lesions after 6 cycles of treatment with carboplatin and paclitaxel.
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ingmenopausal. Prior to her workup, the differential for her skin lesions
was extensive and included contact dermatitis, infection, autoimmune
disorder, and malignancy. Importantly, there was no clear indication
on initial presentation that this patient's skin lesions were a cutaneous
manifestation of internal malignancy, speciﬁcally papillary serous uter-
ine cancer. For this patient, gynecology was initially consulted out of
concern for gynecologic infection. Clues that an underlying malignancy
was present emergedwith further evaluation and included the patient's
unintentional weight loss of 40 lbs. over the last 6 weeks, bulky cervix,
enlarged uterus, and CT ﬁndings. Finally, biopsy of the skin lesions
with comparison to an endometrial biopsy allowed for a deﬁnitive diag-
nosis of metastatic serous carcinoma. This highlights that any patient
with an aggressive cancer and unusual cutaneous lesions should have
such lesions biopsied.
Many different presentations of cutaneous metastases of internal
malignancy have been described. Our patient presented with a pattern
of skin lesions and erythematous, inﬂammatory-appearing skin patches
consistent with carcinoma erysipelatoides. This presentation is com-
monly mistaken for infection and treated as such. In such cases, delay
in diagnosis oftentimes results in delay of effective treatment. Carcino-
ma erysipeloides most commonly occurs near the primary tumor and
can involve ﬁrm, mobile nodules, indurated scar-like plaques from can-
cer cells inﬁltrating collagen, and carcinoma telangiectoides secondary
to cancer cells inﬁltrating blood or lymphatic vessels. Diagnosis of carci-
noma erysipeloides generally requires a biopsy of the involved skin, and
histopathology of the biopsywill revealmalignant cells within the cuta-
neous lymphatics.
Cytotoxic chemotherapy is the primary treatmentmodality of meta-
static uterine cancer with platinum-containing compounds, taxanes,
and anthracyclines being the most commonly utilized agents. The com-
bination of carboplatin and paclitaxel has been shown to demonstrate
an overall response rate of over 60% with median overall survival of
15–26months (Humber et al., 2007). In our patient, this regimen result-
ed in a dramatic improvement in her cutaneous disease, and in overall
tumor burden as evidenced by imaging and CA-125 levels.
Although uterine cancer is the most common gynecologic cancer in
the developed world, skin metastasis is rare with an estimated preva-
lence of 0.8% (Lerner et al., 1999). Skin metastases of uterine cancer
has been described in the literature with a minority of cases involving
serous histology, and with all described cases identifying skin metasta-
sis after primary disease had been identiﬁed (Rasbach et al., 1978;
Damewood et al., 1980; Debois, 1982; Espinos et al., 1992; Spencer et
al., 1994; Kushner et al., 1997; La Fianza et al., 1998; Atallah et al.,2014). To our knowledge, however, skin metastasis as the initial pre-
senting symptomof uterine cancer has not been reported andhighlights
the fact that this rare presentation may occur in the absence of all other
common presenting signs or symptoms of uterine cancer. The case also
demonstrates that a positive response to chemotherapy is possible and,
despite the poor prognosis of stage IV uterine cancer, should be consid-
ered. In summary, the skin is an exceedingly rare site of metastasis of
uterine cancer and it is important for the clinician to recognize thatmet-
astatic uterine cancer can clinically present as skin lesions.
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